Kang H. Hsu is a Harvard-trained peptide structural biologist, Chief Compliance Officer (CCO) of So Young America, an FDA-registered, cGMP manufacturing facility, and CEO of So Young Life Sciences, a biotechnology and pharmaceutical startup. He oversees the development of regenerative medicine focused on the study of cancer. Genes participating in mechanism of disease protein pathways specify a role for a phytocannabinoid botanical drug substance (BDS) to downregulate inflammation and reactive oxidative stress (ROS). Drivers of disease expression in the 34 or more diseases indicate a need for a quality medical-grade phytocannabinoid product. Consequently, he is beginning to explore strategic partnership with sophisticated 420 industry leaders, to classify cultivar chemotypes and supercritical carbon dioxide (CO2) extractors of cannabis concentrates for pediatric brain cancer patients to develop quality assurance (QA)/quality control (QC) supply chains for manufacture of clean, non-toxic current cGMP medicinal cannabis products for families with children suffering from pediatric brain cancer and intractable pediatric epilepsy syndromes through the launching of product lines and the concomitant creation of a trusted brand. He also designed the first pediatric electroencephalogram (EEG) wearable as a combination consumer/medical device to enable parents to monitor and collect clinical data on the efficacy of these product(s) on their child’s brain conditions. He also developed a micro-sized cannabidiol (CBD) oil for better absorption and bioavailability. He is the research member of the team and was instrumental in helping to convince the City of Adelanto to permit cultivation and manufacturing operations within the city.